Recombinant Biotinylated Human GITR / TNFRSF18 Protein, His,Avitag™ (MALS verified), 25 µg

Background
Glucocorticoid-induced TNFR-related protein (GITR) is also known as Tumor necrosis factor receptor superfamily member 18 (TNFRSF18), activation-inducible TNFR family receptor (AITR), CD antigen CD357, which is a member of the tumor necrosis factor receptor (TNF-R) superfamily. GITR is receptor for TNFSF18, which seems to be involved in interactions between activated T-lymphocytes and endothelial cells and in the regulation of T-cell receptor-mediated cell death. GITR also mediated NF-kappa-B activation via the TRAF2/NIK pathway.

Source
Recombinant Biotinylated Human GITR, His,Avitag™ (GIR-H82E1) is expressed from human 293 cells (HEK293). It contains AA Gln 26 - Glu 161 (Accession # Q9Y5U5-1).
Predicted N-terminus: Gln 26

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 18.1 kDa. The protein migrates as 22-26 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
Biotin:Protein Ratio
Passed as determined by the HABA assay / binding ELISA.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1)  "Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonists"
Fromm, de Silva, Schreiber
Front Immunol (2023) 14, 1236332
(2) "DNA damage repair profiling of esophageal squamous cell carcinoma uncovers clinically relevant molecular subtypes with distinct prognoses and therapeutic vulnerabilities"
Zhao, Zhang, Wang et al
EBioMedicine (2023) 96, 104801
(3) "Lung tumor-infiltrating Treg have divergent transcriptional profiles and function linked to checkpoint blockade response"
Dykema, Zhang, Cheung et al
Sci Immunol (2023) 8 (87), eadg1487
Showing 1-3 of 1053 papers.